BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 15538112)

  • 1. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression.
    Erill N; Colomer A; Verdú M; Román R; Condom E; Hannaoui N; Banús JM; Cordon-Cardo C; Puig X
    Diagn Mol Pathol; 2004 Dec; 13(4):217-23. PubMed ID: 15538112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
    Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
    J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards.
    Al-Kashwan TA; Houshmand M; Al-Janabi A; Melconian AK; Al-Abbasi D; Al-Musawi MN; Rostami M; Yasseen AA
    BMC Res Notes; 2012 Aug; 5():466. PubMed ID: 22929185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
    Abdel-Fattah R; Challen C; Griffiths TR; Robinson MC; Neal DE; Lunec J
    Br J Cancer; 1998 Jun; 77(12):2230-8. PubMed ID: 9649138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
    Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
    Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
    Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
    Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.
    Hodgson A; van Rhijn BWG; Kim SS; Ding C; Saleeb R; Vesprini D; Liu SK; Yousef GM; van der Kwast TH; Xu B; Downes MR
    Pathol Res Pract; 2020 Nov; 216(11):153186. PubMed ID: 32861170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
    Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
    Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.
    Smal MP; Rolevich AI; Polyakov SL; Krasny SA; Goncharova RI
    Exp Oncol; 2014 Dec; 36(4):246-51. PubMed ID: 25537218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
    Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
    Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
    Dekairelle AF; Tombal B; Cosyns JP; Gala JL
    Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LOH and mutational analysis of p53 alleles in mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.
    Morimura K; Yamamoto S; Murai T; Mori S; Chen TX; Wanibuchi H; Fukushima S
    Carcinogenesis; 1999 Apr; 20(4):715-8. PubMed ID: 10223204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spectrum of TP53 mutations in bladder carcinoma.
    Williamson MP; Elder PA; Knowles MA
    Genes Chromosomes Cancer; 1994 Feb; 9(2):108-18. PubMed ID: 7513540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
    Olsson H; Hultman P; Rosell J; Söderkvist P; Jahnson S
    BMC Urol; 2013 Jan; 13():5. PubMed ID: 23356517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder.
    Gao JP; Uchida T; Wang C; Jiang SX; Matsumoto K; Satoh T; Minei S; Soh S; Kameya T; Baba S
    Int J Oncol; 2000 Mar; 16(3):469-75. PubMed ID: 10675477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation.
    Cheng HL; Trink B; Tzai TS; Liu HS; Chan SH; Ho CL; Sidransky D; Chow NH
    J Clin Oncol; 2002 Mar; 20(6):1544-50. PubMed ID: 11896103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma.
    Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH
    J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutations and prognosis in bladder tumors.
    Uchida T; Wada C; Ishida H; Wang C; Egawa S; Yokoyama E; Kameya T; Koshiba K
    J Urol; 1995 Apr; 153(4):1097-104. PubMed ID: 7869472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors.
    Cordon-Cardo C; Zhang ZF; Dalbagni G; Drobnjak M; Charytonowicz E; Hu SX; Xu HJ; Reuter VE; Benedict WF
    Cancer Res; 1997 Apr; 57(7):1217-21. PubMed ID: 9102201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
    Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
    J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.